首頁 > 市場調查報告書 > 製藥

處方藥

市場調查報告書

商品編碼

1956581

塔西美替胺市場報告：趨勢、預測和競爭分析（至2031年）

Tasimelteon Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2026年02月25日 | 出版商:

Lucintel | 英文 211 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

受醫院和診所市場機會的推動，全球他西美酮市場預計將成為一個充滿前景的市場。預計2025年至2031年，全球他西美酮市場將以12.1%的複合年成長率成長。這個市場的主要促進因素包括睡眠障礙盛行率的上升、對非成癮性治療方法需求的成長以及人們對晝夜節律紊亂認知的提高。

Lucintel預測，在預測期內，各類學名藥的成長率將高於其他產品類型。
在各類申請類別中，醫院預計將呈現更高的成長率。
從區域來看，預計亞太地區在預測期內將達到最高的成長率。

塔西美替胺市場的新趨勢

受睡眠障礙治療進展和人們對晝夜節律紊亂日益成長的認知的推動，他西美替胺市場正在快速發展。不斷深入的研究和監管核准的擴大為創新治療方法創造了新的機會。市場相關人員正致力於個人化醫療、技術整合和擴大適應症，以滿足不斷成長的患者需求。這些發展正在重塑競爭格局，影響定價策略，並改善病患療效。對於希望掌握市場成長潛力並有效滿足未被滿足的需求的相關人員，了解這些新興趨勢至關重要。

晝夜節律紊亂盛行率上升：晝夜節律紊亂（包括非24小時睡眠-覺醒節律紊亂）盛行率的不斷上升，推動了對tasimelteon的需求。人口老化、輪班工作和生活方式的改變等因素都促成了這一成長。為了應對這一趨勢，製藥公司正在加大研發投入，以改善現有療法並開發新的製劑，從而擴大市場規模並提高患者的用藥可及性。
監管核准與適應症拓展：近期，包括美國食品藥物管理局 (FDA) 在內的多家機構核准他西美坦用於治療非24小時視覺障礙者，增強了市場信心。此外，正在進行的探索其在其他睡眠相關疾病中療效的臨床試驗有望拓展其適應症。這些監管里程碑將加速藥物上市速度，擴大健保覆蓋範圍，並鼓勵投資，從而拓寬治療範圍，提高患者獲得他西美坦的途徑。
科技整合與個人化醫療：睡眠追蹤設備和行動醫療應用程式等數位健康工具的整合正在改變治療效果的監測方式。基於遺傳和生活方式因素的個人化給藥方案正在興起，以改善治療結果。這一趨勢使得治療更具針對性，減少了副作用，並提高了患者的依從性。這使得tasimelteon成為睡眠障礙管理這個更廣泛框架下的個人化解決方案。
提高認知度和診斷率：宣傳活動的加強和診斷技術的進步正在提高晝夜節律紊亂的檢出率。早期診斷有助於及時啟動治療，例如使用他西美酮，從而改善患者的生活品質。這一趨勢促使醫療專業人員更加重視睡眠障礙，推動積極主動的治療方法，並透過提高處方率擴大市場。
競爭格局與市場整合：市場正面臨來自非專利生產商和開發替代療法的新興參與企業的日益激烈的競爭。為了增強產品系列，企業之間普遍進行策略聯盟和併購。這種整合有助於提升研發能力、降低成本並加速創新，最終使患者獲得更多樣化、更經濟實惠的治療選擇。

總而言之，這些新興趨勢正在透過擴大適應症、提高治療個人化和改善可及性，顯著地重塑他西美酮市場，這將促進創新、推動市場成長並改善患者預後，為未來幾年市場的持續發展奠定基礎。

塔西美替胺市場近期趨勢

受睡眠障礙治療進展和人們對晝夜節律紊亂日益成長的認知的推動，他西美酮市場正經歷快速成長。藥物製劑的創新和適應症的拓展為製藥公司創造了新的機遇，而監管部門的核准和策略合作則進一步加速了市場擴張。全球對有效睡眠解決方案日益成長的需求促使相關人員專注於研發，以滿足不同患者的需求。這些趨勢正在創造一個充滿活力的市場環境，為未來的成長和市場主導地位奠定了堅實的基礎。

睡眠障礙的上升趨勢：晝夜節律紊亂（包括<24小時睡眠-覺醒節律紊亂）的發病率不斷上升，推動了對tasimelteon的需求，使其成為重要的治療選擇。這一趨勢刺激了製藥業的投資和研發，促進了市場擴張。醫護人員和病患對睡眠健康的日益重視也進一步推動了產品的普及。隨著人們對睡眠障礙的意識提高，越來越多的患者群體能夠獲得標靶治療，這將推動市場穩步成長。
監管核准與適應症拓展：近期，包括美國食品藥物管理局 (FDA) 在內的監管機構核准了tasimelteon，證實了其療效並使其應用範圍得以擴大。新增適應症，例如時差反應和輪班工作紊亂，正在開闢新的收入來源。這些核准有助於新藥進入市場，並改善新興地區的藥物可近性。簡化的核准流程和積極的臨床試驗結果鼓勵企業加強研發投入，這有望促成更多適應症的核准，並推動市場持續成長。
藥物製劑創新：藥物傳遞系統的進步，包括緩釋製劑，正在提高他西美酮的療效和病人依從性。這些創新減少了給藥頻率，改善了治療效果，使治療更具吸引力。改良的製劑還能最大限度地減少副作用，提高患者的接受度。隨著製藥公司致力於改進製劑，市場將受益於更高的依從性和更廣泛的患者群體，最終提升銷售額和市場佔有率。
策略聯盟與夥伴關係：與製藥公司和研究機構的合作正在加速tasimelteon的研發和商業化。這些夥伴關係有助於我們獲得新技術和開拓新市場，從而增強產品平臺。策略聯盟也支持臨床試驗和監管流程，縮短產品上市時間。這些合作促進創新，豐富產品系列，並鞏固我們的市場地位，確保我們在不斷發展的睡眠障礙治療領域保持持續成長和競爭優勢。
加大研發投入和市場拓展：不斷增加的研發投入正推動他西美酮新製劑和給藥方法的發現。各公司也積極開拓包括新興經濟體在內的尚未開發的市場，以滿足未被滿足的醫療需求。這種對創新和擴張的重視有望提高市場滲透率和收入來源。研發投入的加強將帶來更有效的治療方法，進一步鞏固他西美酮在睡眠障礙治療領域的地位，並支持其長期市場成長。

近期這些進展正透過擴大適應症、改善製劑和加強策略合作，顯著影響他西美酮市場。監管部門的核准和研發投入的增加正在推動創新和市場滲透。隨著全球對睡眠障礙的認知不斷提高，該市場有望持續成長，為相關人員帶來新的機會。總而言之，這些進展有望創造一個競爭激烈且充滿創新的環境，以滿足不同患者的需求並改善治療效果。

The future of the global tasimelteon market looks promising with opportunities in the hospital and clinic markets. The global tasimelteon market is expected to grow with a CAGR of 12.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of sleep disorders, the rising demand for non-habit forming treatments, and the growing awareness of circadian rhythm disruptions.

Lucintel forecasts that, within the type category, generic drug is expected to witness higher growth over the forecast period.
Within the application category, hospital is expected to witness higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Tasimelteon Market

The tasimelteon market is experiencing rapid evolution driven by advancements in sleep disorder treatments and increasing awareness of circadian rhythm disorders. As research progresses and regulatory approvals expand, new opportunities emerge for innovative therapies. Market players are focusing on personalized medicine, technological integration, and expanding indications to meet growing patient needs. These developments are reshaping the competitive landscape, influencing pricing strategies, and enhancing patient outcomes. Understanding these emerging trends is crucial for stakeholders aiming to capitalize on the markets growth potential and address unmet medical needs effectively.

Growing Prevalence of Circadian Rhythm Disorders: The increasing incidence of conditions like Non-24-Hour Sleep-Wake Disorder (Non-24) and other circadian rhythm disruptions is driving demand for Tasimelteon. Factors such as aging populations, shift work, and lifestyle changes contribute to this rise. This trend prompts pharmaceutical companies to invest in research and development to improve existing therapies and develop new formulations, ultimately expanding market size and accessibility for affected patients.
Regulatory Approvals and Expanded Indications: Recent approvals by agencies like the FDA for Tasimelteon in treating Non-24 in blind individuals have boosted market confidence. Additionally, ongoing clinical trials exploring its efficacy for other sleep-related disorders are likely to lead to expanded indications. These regulatory milestones facilitate market entry, increase insurance coverage, and encourage investment, thereby broadening the therapeutic scope and increasing patient access to Tasimelteon.
Technological Integration and Personalized Medicine: The integration of digital health tools, such as sleep tracking devices and mobile health apps, is transforming how treatment efficacy is monitored. Personalized dosing regimens based on genetic and lifestyle factors are emerging, enhancing treatment outcomes. This trend allows for more targeted therapies, reduces adverse effects, and improves patient adherence, positioning Tasimelteon as a tailored solution within the broader sleep disorder management landscape.
Rising Awareness and Diagnosis Rates: Increased awareness campaigns and improved diagnostic techniques are leading to higher detection rates of circadian rhythm disorders. Early diagnosis enables timely intervention with therapies like Tasimelteon, improving patients quality of life. This trend also encourages healthcare providers to consider sleep disorders more seriously, fostering a proactive approach to treatment and expanding the market through higher prescription rates.
Competitive Landscape and Market Consolidation: The market is witnessing increased competition from generic manufacturers and new entrants developing alternative therapies. Strategic collaborations, mergers, and acquisitions are common as companies aim to strengthen their portfolios. This consolidation enhances research capabilities, reduces costs, and accelerates innovation, ultimately benefiting patients through more diverse treatment options and potentially lower prices.

In summary, these emerging trends are significantly reshaping the tasimelteon market by expanding its scope, improving treatment personalization, and increasing accessibility. They foster innovation, drive market growth, and enhance patient outcomes, positioning the market for sustained development in the coming years.

Recent Developments in the Tasimelteon Market

The tasimelteon market is experiencing rapid growth driven by advancements in sleep disorder treatments and increased awareness of circadian rhythm disorders. Innovations in drug formulations and expanding indications are opening new opportunities for pharmaceutical companies. Regulatory approvals and strategic collaborations are further accelerating market expansion. As the demand for effective sleep solutions rises globally, stakeholders are focusing on research and development to meet diverse patient needs. These developments are shaping a dynamic landscape with significant potential for future growth and market dominance.

Growing Prevalence of Sleep Disorders: Increasing cases of non-24-hour sleep-wake disorder and other circadian rhythm disruptions are driving demand for Tasimelteon, positioning it as a vital treatment option. This trend encourages pharmaceutical investments and research, expanding market reach. The rising awareness among healthcare providers and patients about sleep health further boosts product adoption. As sleep disorders become more recognized, the market is expected to grow steadily, with new patient populations gaining access to targeted therapies.
Regulatory Approvals and Expanded Indications: Recent approvals by regulatory agencies like the FDA have validated Tasimelteon's efficacy, enabling broader use. Expanded indications for conditions such as jet lag disorder and shift work disorder are opening new revenue streams. These approvals facilitate market entry in emerging regions, increasing accessibility. The streamlined approval process and positive clinical trial outcomes are encouraging companies to invest in further research, which will likely lead to additional indications and sustained market growth.
Innovation in Drug Formulations: Advances in drug delivery systems, including sustained-release formulations, are enhancing Tasimelteon's effectiveness and patient compliance. These innovations reduce dosing frequency and improve therapeutic outcomes, making the treatment more appealing. Improved formulations also minimize side effects, increasing patient acceptance. As pharmaceutical companies focus on formulation improvements, the market will benefit from increased adherence and expanded patient base, ultimately boosting sales and market share.
Strategic Collaborations and Partnerships: Collaborations between pharmaceutical firms and research institutions are accelerating Tasimelteon development and commercialization. These partnerships facilitate access to new technologies and markets, enhancing product pipelines. Strategic alliances also support clinical trials and regulatory processes, reducing time-to-market. Such collaborations foster innovation, diversify product portfolios, and strengthen market positioning, ensuring sustained growth and competitive advantage in the evolving sleep disorder treatment landscape.
Increasing Investment in R&D and Market Expansion: Rising investments in research and development are driving the discovery of new formulations and delivery methods for Tasimelteon. Companies are also expanding into untapped markets, including emerging economies, to capitalize on unmet needs. This focus on innovation and expansion is expected to increase market penetration and revenue streams. Enhanced R&D efforts will likely lead to improved therapies, further solidifying Tasimelteon's role in sleep disorder management and supporting long-term market growth.

Conclusion (80 Words) - These recent developments are significantly impacting the tasimelteon market by expanding its applications, improving formulations, and fostering strategic collaborations. Regulatory approvals and increased R&D investments are driving innovation and market penetration. As awareness of sleep disorders grows globally, the market is poised for sustained growth, offering new opportunities for stakeholders. Overall, these advancements are shaping a competitive, innovative landscape that promises to meet diverse patient needs and enhance treatment outcomes.

Strategic Growth Opportunities in the Tasimelteon Market

The tasimelteon market is poised for significant expansion driven by the increasing prevalence of sleep disorders, aging populations, and advancements in sleep disorder treatments. Rising awareness and regulatory approvals are opening new avenues for product development and market penetration. Strategic collaborations and technological innovations further enhance growth prospects. As healthcare providers seek effective solutions for circadian rhythm disorders, the market is expected to witness robust demand, creating opportunities for manufacturers, researchers, and stakeholders to capitalize on emerging needs.

Expanding Use in Treatment of Non-24-Hour Sleep-Wake Disorder: Tasimelteon's approval for Non-24-Hour Sleep-Wake Disorder, primarily affecting blind individuals, presents a substantial growth opportunity. Increasing diagnosis rates and awareness are driving demand. The drug's efficacy in regulating circadian rhythms positions it as a preferred treatment, encouraging pharmaceutical companies to invest in marketing and distribution. Ongoing research may extend its application to other sleep-related conditions, further broadening market scope and revenue potential.
Growing Demand Due to Rising Prevalence of Sleep Disorders: The global rise in sleep disorders, including insomnia and circadian rhythm disruptions, fuels the need for targeted therapies like Tasimelteon. Aging populations and lifestyle factors contribute to this trend. Healthcare providers are increasingly adopting pharmacological solutions, boosting sales. Market players are focusing on expanding access through clinical trials and regulatory approvals in new regions, which will enhance product availability and stimulate overall market growth.
Strategic Collaborations and Licensing Agreements to Accelerate Market Penetration: Companies are forming strategic alliances to enhance Tasimelteon's market reach. Licensing agreements facilitate entry into emerging markets with regulatory support, reducing time-to-market. Collaborations with research institutions foster innovation and new formulation development. These partnerships enable resource sharing, risk mitigation, and increased marketing efforts, ultimately accelerating adoption rates and expanding the customer base, thereby strengthening the market position of key players.
Technological Innovations and Formulation Improvements to Enhance Efficacy: Advances in drug delivery systems and formulation techniques are improving Tasimelteon's bioavailability and patient compliance. Novel delivery methods, such as sustained-release formulations, can extend therapeutic effects and reduce dosing frequency. These innovations increase treatment adherence and satisfaction, leading to higher market acceptance. Continuous R&D investments are expected to yield more effective, safer, and user-friendly products, further driving market growth and competitive advantage.
Increasing Regulatory Approvals and Market Expansion in Emerging Economies: Regulatory approvals in new regions are opening untapped markets for Tasimelteon. Governments are recognizing sleep disorders as a healthcare priority, facilitating faster approval processes. Market expansion strategies include local manufacturing and partnerships with regional distributors. This growth in emerging economies offers significant revenue opportunities, diversifies market risk, and supports global market expansion, ultimately contributing to the overall growth trajectory of the tasimelteon market.

The overall impact of these opportunities is a robust growth trajectory for the tasimelteon market, driven by technological, regulatory, and demographic factors. Strategic initiatives and expanding applications will enhance market competitiveness and accessibility. As awareness and demand increase, stakeholders are positioned to benefit from sustained growth, innovation, and improved patient outcomes, shaping a promising future for the industry.

Tasimelteon Market Driver and Challenges

The tasimelteon market is influenced by a variety of technological, economic, and regulatory factors that shape its growth trajectory. Advances in pharmaceutical research and development have led to innovative formulations and targeted therapies, boosting market potential. Economic factors such as increasing healthcare expenditure and rising prevalence of sleep disorders further propel demand. Regulatory approvals and supportive government policies facilitate market entry and expansion. However, challenges like stringent regulatory requirements, high R&D costs, and patent expirations pose significant hurdles. Understanding these drivers and challenges is essential for stakeholders to navigate the complex landscape and capitalize on emerging opportunities effectively.

The factors responsible for driving the tasimelteon market include:-

Technological Advancements: The development of novel drug delivery systems and formulations enhances drug efficacy and patient compliance, fostering market growth. Continuous innovation in pharmacology and clinical research accelerates the approval of new indications, expanding the market scope. Additionally, advancements in diagnostic tools improve patient identification, ensuring targeted therapy and better outcomes, which in turn increases demand for Tasimelteon.
Rising Prevalence of Sleep Disorders: Increasing incidences of conditions like Non-24-Hour Sleep-Wake Disorder and other circadian rhythm sleep disorders, especially among blind and elderly populations, drive the need for effective treatments. Growing awareness and diagnosis rates contribute to higher prescription rates, supporting market expansion. The aging population worldwide further amplifies this demand, as sleep disorders are more prevalent among older adults.
Regulatory Approvals and Supportive Policies: Approval from regulatory bodies such as the FDA and EMA for Tasimelteon as a treatment for specific sleep disorders boosts market confidence. Supportive policies promoting research and development in sleep medicine facilitate faster drug approvals and market entry. Additionally, reimbursement policies and insurance coverage improve patient access, encouraging widespread adoption.
Increasing Healthcare Expenditure: Rising healthcare spending globally enables better access to advanced therapies like Tasimelteon. Investments in sleep disorder management programs and clinical research foster innovation and market growth. The expanding healthcare infrastructure, especially in emerging economies, provides new opportunities for market players to introduce and promote Tasimelteon.

The challenges in the tasimelteon market are:

Stringent Regulatory Requirements: Navigating complex approval processes and meeting safety and efficacy standards can delay product launches and increase costs. Regulatory agencies often require extensive clinical data, which prolongs development timelines and impacts profitability. Variability in regulatory frameworks across regions adds to the complexity, requiring strategic planning for global market entry.
High R&D Costs and Time: Developing new formulations and conducting comprehensive clinical trials demand significant financial investment and time. These costs can be prohibitive for smaller companies and may hinder innovation. The lengthy development cycle also exposes companies to market risks, such as changing regulatory landscapes and competitive pressures.
Patent Expirations and Generic Competition: The expiration of patents for key formulations opens the market to generic competitors, leading to price erosion and reduced profit margins. This intensifies competition and pressures companies to innovate continuously. Maintaining market share becomes challenging as generic versions offer similar efficacy at lower prices, impacting revenue streams.

In summary, the tasimelteon market is driven by technological innovations, increasing sleep disorder prevalence, regulatory support, and rising healthcare expenditure. However, it faces challenges from regulatory complexities, high R&D costs, and patent expirations. These factors collectively influence market dynamics, requiring stakeholders to strategize effectively. While growth opportunities are substantial, addressing the challenges is crucial for sustained success. Overall, the markets future depends on balancing innovation with regulatory and competitive considerations to meet the growing demand for sleep disorder treatments.

List of Tasimelteon Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tasimelteon companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tasimelteon companies profiled in this report include-

Vanda Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Lupin Limited
Zydus Lifesciences Limited
Dr. Reddys Laboratories Ltd.
Aurobindo Pharma Limited

Tasimelteon Market by Segment

The study includes a forecast for the global tasimelteon market by type, distribution channel, application, end use, and region.

Tasimelteon Market by Type [Value from 2019 to 2031]:

Original Drug
Generic Drug

Tasimelteon Market by Distribution Channel [Value from 2019 to 2031]:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Tasimelteon Market by Application [Value from 2019 to 2031]:

Hospital
Clinic
Others

Tasimelteon Market by End Use [Value from 2019 to 2031]:

Adult Population
Geriatric Population
Shift Workers
Others

Tasimelteon Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Tasimelteon Market

The tasimelteon market has experienced notable developments driven by increasing awareness of circadian rhythm disorders and advancements in pharmaceutical research. As a treatment for conditions like Non-24-Hour Sleep-Wake Disorder, especially among blind individuals, the markets growth is influenced by regulatory approvals, technological innovations, and expanding clinical applications. Countries are adopting new strategies to enhance drug accessibility and improve patient outcomes, reflecting a global focus on sleep health. These developments are shaping the future landscape of the tasimelteon market, with key players investing in research and expanding their geographic reach to meet rising demand.

United States: The US market has seen significant growth due to FDA approval of Tasimelteon for Non-24-Hour Sleep-Wake Disorder. Increased awareness and insurance coverage have improved patient access. Major pharmaceutical companies are investing in clinical trials to explore additional indications, and technological advancements in drug delivery systems are enhancing efficacy. The government's focus on sleep health research further supports market expansion, with a rising number of clinical studies and partnerships driving innovation.
China: China's tasimelteon market is emerging, supported by increasing prevalence of sleep disorders and rising healthcare expenditure. Local pharmaceutical companies are investing in research collaborations to develop generic versions and improve drug accessibility. Regulatory pathways are becoming more streamlined, encouraging market entry. Additionally, growing awareness about sleep health and government initiatives to improve healthcare infrastructure are contributing to market growth, although the market remains relatively nascent compared to Western countries.
Germany: In Germany, the market benefits from a well-established healthcare system and high awareness of sleep disorders. Regulatory approval processes are efficient, facilitating quicker market access for new formulations and indications. The country's focus on personalized medicine and technological integration in healthcare is fostering innovative approaches to Tasimelteon therapy. Collaborations between academic institutions and pharmaceutical companies are advancing research, and reimbursement policies are favorable, supporting broader patient access.
India: The Indian tasimelteon market is in its early stages but shows promising growth potential due to increasing awareness of sleep disorders and rising healthcare investments. Local manufacturers are exploring cost-effective manufacturing options to make the drug more affordable. Government initiatives aimed at improving healthcare infrastructure and increasing sleep disorder diagnosis rates are driving demand. Additionally, the expanding pharmaceutical sector and rising prevalence of sleep-related issues among the population are expected to propel market development.
Japan: Japan's market is characterized by high healthcare standards and a focus on sleep health management. Regulatory approval processes are rigorous but efficient, enabling timely access to Tasimelteon. The aging population and increasing prevalence of sleep disorders are key drivers. Japan is also investing in research to explore new therapeutic uses of Tasimelteon, with collaborations between biotech firms and academic institutions. Reimbursement policies and a strong emphasis on innovative treatments support the market's steady growth and adoption.

Features of the Global Tasimelteon Market

Market Size Estimates: Tasimelteon market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Tasimelteon market size by various segments, such as by type, distribution channel, application, end use, and region in terms of value ($B).
Regional Analysis: Tasimelteon market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, applications, end uses, and regions for the tasimelteon market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tasimelteon market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the tasimelteon market by type (original drug and generic drug), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (hospital, clinic, and others), end use (adult population, geriatric population, shift workers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Tasimelteon Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Original Drug : Trends and Forecast (2019-2031)
4.4 Generic Drug : Trends and Forecast (2019-2031)

5. Global Tasimelteon Market by Distribution Channel

5.1 Overview
5.2 Attractiveness Analysis by Distribution Channel
5.3 Hospital Pharmacies : Trends and Forecast (2019-2031)
5.4 Retail Pharmacies : Trends and Forecast (2019-2031)
5.5 Online Pharmacies : Trends and Forecast (2019-2031)

6. Global Tasimelteon Market by Application

6.1 Overview
6.2 Attractiveness Analysis by Application
6.3 Hospital : Trends and Forecast (2019-2031)
6.4 Clinic : Trends and Forecast (2019-2031)
6.5 Others : Trends and Forecast (2019-2031)

7. Global Tasimelteon Market by End Use

7.1 Overview
7.2 Attractiveness Analysis by End Use
7.3 Adult Population : Trends and Forecast (2019-2031)
7.4 Geriatric Population : Trends and Forecast (2019-2031)
7.5 Shift Workers : Trends and Forecast (2019-2031)
7.6 Others : Trends and Forecast (2019-2031)

8. Regional Analysis

8.1 Overview
8.2 Global Tasimelteon Market by Region

9. North American Tasimelteon Market

9.1 Overview
9.2 North American Tasimelteon Market by Type
9.3 North American Tasimelteon Market by Application
9.4 The United States Tasimelteon Market
9.5 Canadian Tasimelteon Market
9.6 Mexican Tasimelteon Market

10. European Tasimelteon Market

10.1 Overview
10.2 European Tasimelteon Market by Type
10.3 European Tasimelteon Market by Application
10.4 German Tasimelteon Market
10.5 French Tasimelteon Market
10.6 Italian Tasimelteon Market
10.7 Spanish Tasimelteon Market
10.8 The United Kingdom Tasimelteon Market

11. APAC Tasimelteon Market

11.1 Overview
11.2 APAC Tasimelteon Market by Type
11.3 APAC Tasimelteon Market by Application
11.4 Chinese Tasimelteon Market
11.5 Indian Tasimelteon Market
11.6 Japanese Tasimelteon Market
11.7 South Korean Tasimelteon Market
11.8 Indonesian Tasimelteon Market

12. ROW Tasimelteon Market

12.1 Overview
12.2 ROW Tasimelteon Market by Type
12.3 ROW Tasimelteon Market by Application
12.4 Middle Eastern Tasimelteon Market
12.5 South American Tasimelteon Market
12.6 African Tasimelteon Market

13. Competitor Analysis

13.1 Product Portfolio Analysis
13.2 Operational Integration
13.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

14.1 Value Chain Analysis
14.2 Growth Opportunity Analysis
- 14.2.1 Growth Opportunity by Type
- 14.2.2 Growth Opportunity by Distribution Channel
- 14.2.3 Growth Opportunity by Application
- 14.2.4 Growth Opportunity by End Use
14.3 Emerging Trends in the Global Tasimelteon Market
14.4 Strategic Analysis
- 14.4.1 New Product Development
- 14.4.2 Certification and Licensing
- 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

15.1 Competitive Analysis Overview
15.2 Vanda Pharmaceuticals Inc.
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.3 Teva Pharmaceutical Industries Ltd.
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.4 Sun Pharmaceutical Industries Ltd.
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.5 Lupin Limited
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.6 Zydus Lifesciences Limited
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.7 Dr. Reddy's Laboratories Ltd.
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.8 Aurobindo Pharma Limited
- Company Overview
- Tasimelteon Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

16. Appendix

16.1 List of Figures
16.2 List of Tables
16.3 Research Methodology
16.4 Disclaimer
16.5 Copyright
16.6 Abbreviations and Technical Units
16.7 About Us
16.8 Contact Us

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

塔西美替胺市場報告：趨勢、預測和競爭分析（至2031年）

Tasimelteon Market Report: Trends, Forecast and Competitive Analysis to 2031

目錄

第1章執行摘要

第2章 市場概覽

第3章：市場趨勢與預測分析

4. 全球他西美替胺市場（按類型分類）

5. 全球他西美替胺市場按分銷管道分類

6. 全球他西美酮市場按應用領域分類

7. 全球他西美酮市場依最終用途分類

第8章 區域分析

第9章 北美塔西美替胺市場

第10章 歐洲塔西美替胺市場

第11章：亞太地區泰西美替胺市場

第12章 其他地區的塔西梅爾特昂市場

第13章 競爭分析

第14章：機會與策略分析

第15章 價值鏈主要企業的公司概況

第16章附錄